Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Kagan

Internal Medicine Brockton, MA Medical Doctor

NPI 1851388029 CMS profile 38263

1 Pearl St, Suite 2100, Brockton, MA 02301

Open in the dashboard

General payments

$18,741

1,104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Kagan of Brockton, MA is reported in the CMS Open Payments database as having received $18,741 across 1,104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,268 175
2024 General $3,090 173
2023 General $2,795 163
2022 General $2,091 125
2021 General $3,488 213
2020 General $2,052 129
2019 General $1,956 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Kagan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Joseph Kagan were reported at $3,268. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Joseph Kagan Internal Medicine median Middle half National median
2019 $1,956 $159 $48–$570 $163
2020 $2,052 $119 $33–$402 $114
2021 $3,488 $135 $37–$521 $132
2022 $2,091 $141 $42–$496 $149
2023 $2,795 $149 $45–$519 $160
2024 $3,090 $154 $47–$537 $164
2025 $3,268 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,747 119 payments
  2. AbbVie, Inc. $1,705 105 payments
  3. Novo Nordisk Inc $1,553 89 payments
  4. Amgen Inc. $1,289 76 payments
  5. Lilly USA, LLC $1,232 69 payments
  6. AstraZeneca Pharmaceuticals LP $1,231 57 payments
  7. Novartis Pharmaceuticals Corporation $923 94 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $729 29 payments
  9. Esperion Therapeutics, Inc. $665 39 payments
  10. Merck Sharp & Dohme Corporation $613 32 payments
  11. Other $7,054 395 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,663 1,093 payments
  2. Education $78 11 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $934 46 payments
  2. Ozempic $696 36 payments
  3. NEXLETOL $665 39 payments
  4. FARXIGA $660 30 payments
  5. LEQVIO $592 53 payments
  6. EVENITY $582 33 payments
  7. RYBELSUS $576 30 payments
  8. NURTEC ODT Pain $564 44 payments
  9. NURTEC ODT Primary Care $554 47 payments
  10. Prolia $535 31 payments
  11. Other $19,634 1,147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 133 drugs

Part D claims

9,568

Median for Internal Medicine: 777

Drug cost

$1,352,272

Median for Internal Medicine: $73,373

Branded share of claims

22%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 371 $397,693
Eliquis Apixaban Brand 172 $202,799
Otezla Apremilast Brand 21 $116,434
Repatha Sureclick Evolocumab Brand 79 $57,052
Jardiance Empagliflozin Brand 35 $54,796
Mounjaro Tirzepatide Brand 43 $46,940
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $37,538
Farxiga Dapagliflozin Propanediol Brand 41 $35,186
Vraylar Cariprazine Hcl Brand 17 $35,041
Vascepa Icosapent Ethyl Brand 39 $27,864

The 10 drugs with the highest cost, of 133 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$226,216

Of which drugs: $70,951

Medicare patients

329

Average age 75

Services billed

7,392

168 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 54%
Diabetes 26%
Depression 25%
Ischemic heart disease 20%
Cancer 19%
Atrial fibrillation 16%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 21 1,744 $36,325
Pcv20 vaccine im 90677 Office 57 58 $16,391
Vaccine for influenza for injection into muscle 90653 Office 107 107 $8,653
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 22 70 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$250 17 —
Wegovy
$201 15 —
AIRSUPRA
$197 — —
LEQVIO
$153 — —
NURTEC ODT
$115 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

1,104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record